Affluent Medical signed a cooperation agreement with Edwards Lifesciences covering an exclusive option on Kalios technology, a non-exclusive license for mitral valve replacement IP, and an equity stake. Edwards will pay a total of €15 million in prepayments.
Edwards Lifesciences agreed to pay 15 million euros (about $16.3 million) for a 9.21% equity stake in France's Affluent Medical, including an exclusive option to buy its mitral ring subsidiary and a global license for biomimetic mitral valve replacement technology.
Affluent Medical signed several agreements with Edwards Lifesciences on July 12, 2024, for its mitral valve technologies, including an exclusive option to acquire Kephalios, a license for biomimetic cardiac mitral valve replacement technology, and an equity stake, with EUR 15 million upfront payment.